Caplyta’s unanticipated schizophrenia approval lifts Intra-Cellular shares

Emerging from a cloud of regulatory questions and mixed clinical results, Intra-Cellular has received FDA approval of Caplyta lumateperone for schizophrenia, sending the company’s shares up 193% to $36.51 on Monday.

The stock move added more than $1.3 billion to the company’s market cap...